共查询到20条相似文献,搜索用时 15 毫秒
1.
Zhenrong Xu Salvacion Cacatian Jing Yuan Robert D. Simpson Lanqi Jia Wei Zhao Colin M. Tice Patrick T. Flaherty Joan Guo Alexey Ishchenko Suresh B. Singh Zhongren Wu Brian M. McKeever Boyd B. Scott Yuri Bukhtiyarov Jennifer Berbaum Jennifer Mason Reshma Panemangalore Maria Grazia Cappiello Ross Bentley David A. Claremon 《Bioorganic & medicinal chemistry letters》2010,20(2):694-699
Structure-guided drug design led to new alkylamine renin inhibitors with improved in vitro and in vivo potency. Lead compound 21a, has an IC50 of 0.83 nM for the inhibition of human renin in plasma (PRA). Oral administration of 21a at 10 mg/kg resulted in >20 h reduction of blood pressure in a double transgenic rat model of hypertension. 相似文献
2.
Paul E. Harrington Matthew P. Bourbeau Christopher Fotsch Michael Frohn Alexander J. Pickrell Andreas Reichelt Kelvin Sham Aaron C. Siegmund Julie M. Bailis Tammy Bush Sonia Escobar Dean Hickman Scott Heller Faye Hsieh Jessica N. Orf Minqing Rong Tisha San Miguel Helming Tan John G. Allen 《Bioorganic & medicinal chemistry letters》2013,23(23):6396-6400
A series of aminooxadiazoles was optimized for inhibition of Cdc7. Early lead isoquinoline 1 suffered from modest cell potency (cellular IC50 = 0.71 μM measuring pMCM2), low selectivity against structurally related kinases, and high IV clearance in rats (CL = 18 L/h/kg). Extensive optimization resulted in azaindole 26 (Cdc7 IC50 = 1.1 nM, pMCM2 IC50 = 32 nM) that demonstrated robust lowering of pMCM2 in a mouse pharmacodynamic (PD) model when dosed orally. Modifications to improve the pharmacokinetic profile of this series were guided by trapping experiments with glutathione in rat hepatocytes. 相似文献
3.
《Bioorganic & medicinal chemistry》2016,24(6):1183-1190
Human reticulocyte 12/15-lipoxygenase (h12/15-LOX) is a lipid-oxidizing enzyme that can directly oxidize lipid membranes in the absence of a phospholipase, leading to a direct attack on organelles, such as the mitochondria. This cytotoxic activity of h12/15-LOX is up-regulated in neurons and endothelial cells after a stroke and thought to contribute to both neuronal cell death and blood–brain barrier leakage. The discovery of inhibitors that selectively target recombinant h12/15-LOX in vitro, as well as possessing activity against the murine ortholog ex vivo, could potentially support a novel therapeutic strategy for the treatment of stroke. Herein, we report a new family of inhibitors discovered in a High Throughput Screen (HTS) that are selective and potent against recombinant h12/15-LOX and cellular mouse 12/15-LOX (m12/15-LOX). MLS000099089 (compound 99089), the parent molecule, exhibits an IC50 potency of 3.4 ± 0.5 μM against h12/15-LOX in vitro and an ex vivo IC50 potency of approximately 10 μM in a mouse neuronal cell line, HT-22. Compound 99089 displays greater than 30-fold selectivity versus h5-LOX and COX-2, 15-fold versus h15-LOX-2 and 10-fold versus h12-LOX, when tested at 20 μM inhibitor concentration. Steady-state inhibition kinetics reveals that the mode of inhibition of 99089 against h12/15-LOX is that of a mixed inhibitor with a Kic of 1.0 ± 0.08 μM and a Kiu of 6.0 ± 3.3 μM. These data indicate that 99089 and related derivatives may serve as a starting point for the development of anti-stroke therapeutics due to their ability to selectively target h12/15-LOX in vitro and m12/15-LOX ex vivo. 相似文献
4.
Shaogao Zeng Hui Xie Li-li Zeng Xin Lu Xin Zhao Gui-cheng Zhang Zheng-chao Tu Hong-jiang Xu Ling Yang Xi-quan Zhang Wenhui Hu 《Bioorganic & medicinal chemistry》2013,21(7):1749-1755
A novel dipeptidyl peptidase IV inhibitor hit (5, IC50 = 0.86 μM) was structurally derived from our recently disclosed preclinical candidate 4 by replacing the cyanobenzyl with a butynyl based on pharmacophore hybridization. A hit-to-lead optimization effort was then initiated to improve its potency. Most N-substituted analogs exhibited good in vitro activity, and compound 18o (IC50 = 1.55 nM) was identified to be a potent dipeptidyl peptidase IV inhibitor with a significantly improved pharmacokinetic properties (bioavailablity: 41% vs 82.9%; T1/2: 2 h vs 4.9 h). 相似文献
5.
John W. Anderson Dimitri Sarantakis Jacek Terpinski T.R. Santha Kumar Han-Chun Tsai Mack Kuo Arba L. Ager William R. Jacobs Guy A. Schiehser Sean Ekins James C. Sacchettini David P. Jacobus David A. Fidock Joel S. Freundlich 《Bioorganic & medicinal chemistry letters》2013,23(4):1022-1025
Exploration of triclosan analogs has led to novel diaryl ureas with significant potency against in vitro cultures of drug-resistant and drug-sensitive strains of the human malaria parasite Plasmodium falciparum. Compound 18 demonstrated EC50 values of 37 and 55 nM versus in vitro cultured parasite strains and promising in vivo efficacy in a Plasmodium berghei antimalarial mouse model, with >50% survival at day 31 post-treatment when administered subcutaneously at 256 mg/kg. This series of compounds provides a chemical scaffold of novel architecture, as validated by cheminformatics analysis, to pursue antimalarial drug discovery efforts. 相似文献
6.
Yasuo Yamamoto Eiji Kawanishi Yuichi Koga Shigeki Sakamaki Toshiaki Sakamoto Kiichiro Ueta Yasuaki Matsushita Chiaki Kuriyama Minoru Tsuda-Tsukimoto Sumihiro Nomura 《Bioorganic & medicinal chemistry letters》2013,23(20):5641-5645
Inhibition of renal sodium-dependent glucose cotransporter 2 (SGLT2) increases urinary glucose excretion (UGE), and thus reduces blood glucose levels in hyperglycemia. A series of N-glucosides was synthesized for biological evaluation as human SGLT2 (hSGLT2) inhibitors. Among these compounds, N-glucoside 9d possessing an indole core structure showed good in vitro activity (IC50 = 7.1 nM against hSGLT2). Furthermore, 9d exhibited favorable in vivo potency with regard to UGE in rats based on good pharmacokinetic profiles. 相似文献
7.
《Bioorganic & medicinal chemistry letters》2014,24(1):337-343
A co-crystal structure of amide-containing compound (4) in complex with the nicotinamide phosphoribosyltransferase (Nampt) protein and molecular modeling were utilized to design and discover a potent novel cyanoguanidine-containing inhibitor bearing a sulfone moiety (5, Nampt Biochemical IC50 = 2.5 nM, A2780 cell proliferation IC50 = 9.7 nM). Further SAR exploration identified several additional cyanoguanidine-containing compounds with high potency and good microsomal stability. Among these, compound 15 was selected for in vivo profiling and demonstrated good oral exposure in mice. It also exhibited excellent in vivo antitumor efficacy when dosed orally in an A2780 ovarian tumor xenograft model. The co-crystal structure of this compound in complex with the NAMPT protein was also determined. 相似文献
8.
Maria A.F. Vera-DiVaio Antônio C.C. Freitas Helena C. Castro Sérgio de Albuquerque Lucio M. Cabral Carlos R. Rodrigues Magaly G. Albuquerque Rita C.A. Martins Maria G.M.O. Henriques Luiza R.S. Dias 《Bioorganic & medicinal chemistry》2009,17(1):295-302
Chagas disease (American trypanosomiasis) is one of the most important parasitic diseases with serious social and economic impacts mainly on Latin America. This work reports the synthesis, in vitro trypanocidal evaluation, cytotoxicity assays, and molecular modeling and SAR/QSAR studies of a new series of N-phenylpyrazole benzylidene-carbohydrazides. The results pointed 6k (X = H, Y = p-NO2, pIC50 = 4.55 M) and 6l (X = F, Y = p-CN, pIC50 = 4.27 M) as the most potent derivatives compared to crystal violet (pIC50 = 3.77 M). The halogen-benzylidene-carbohydrazide presented the lowest potency whereas 6l showed the most promising profile with low toxicity (0% of cell death). The best equation from the 4D-QSAR analysis (Model 1) was able to explain 85% of the activity variability. The QSAR graphical representation revealed that bulky X-substituents decreased the potency whereas hydrophobic and hydrogen bond acceptor Y-substituents increased it. 相似文献
9.
《Bioorganic & medicinal chemistry letters》2014,24(10):2288-2294
Two novel series of spirocyclic piperidine analogs appended to a pyrazolo[1,5-a]pyridine core were designed, synthesized and evaluated for their anti-HCV activity. A series of piperidine ketals afforded dispiro 6p which showed excellent in vitro anti-HCV activities (EC50 of 1.5 nM and 1.2 nM against genotype 1a and 1b replicons, respectively). A series of piperidine oxazolidinones afforded 27c which showed EC50’s of 10.9 nM and 6.1 nM against 1a and 1b replicons, respectively. Both compounds 6p and 27c bound directly to non-structural NS4B protein in vitro (IC50’s = 10.2 and 30.4 nM, respectively) and exhibited reduced potency in replicons containing resistance mutations encoding changes in the NS4B protein. 相似文献
10.
Ashok Kumar Kumkum Srivastava S. Raja Kumar S.K. Puri Prem M.S. Chauhan 《Bioorganic & medicinal chemistry letters》2009,19(24):6996-6999
There is challenge and urgency to synthesize cost-effective chemotherapeutic agents for treatment of malaria after the widespread development of resistance to CQ. In the present study, we synthesized a new series of hybrid 9-anilinoacridine triazines using the cheap chemicals 6,9-dichloro-2-methoxy acridine and cyanuric chloride. The series of new hybrid 9-anilinoacridine triazines were evaluated in vitro for their antimalarial activity against CQ-sensitive 3D7 strain of Plasmodium falciparum and their cytotoxicity were determined on VERO cell line. Of the evaluated compounds, two compounds 17 (IC50 = 4.21 nM) and 22 (IC50 = 4.27 nM) displayed two times higher potency than CQ (IC50 = 8.15 nM). Most of the compounds showed fairly high selectivity index. The compounds 13 and 29 displayed >96.59% and 98.73% suppression, respectively, orally against N-67 strain of Plasmodium yoelii in swiss mice at dose 100 mg/kg for four days. 相似文献
11.
Jung-eun Park Chiman Song Keehyun Choi Taebo Sim Bongjin Moon Eun Joo Roh 《Bioorganic & medicinal chemistry letters》2013,23(20):5515-5518
A series of 3,4-diarylpyrrolidin-2-one was designed, prepared and evaluated as triple reuptake inhibitors for antidepressant. Most compounds exhibited comparable in vitro efficacy as norepinephrine and dopamine transporter reuptake inhibitors. Especially, 2i showed better potency than GBR-12909 (IC50 = 14 nM) which was used as reference compound for dopamine transporter. In addition, 2a and 2b showed inhibition (5.17 μM–85.6 nM) for three transporters. 相似文献
12.
Abdel-Sattar S. Hamad Elgazwy Nasser S.M. Ismail Heba S.A. Elzahabi 《Bioorganic & medicinal chemistry》2010,18(21):7639-7650
A series of novel purine and pyrimidine derivatives were prepared and biologically evaluated for their in vitro anti-CDK2/cyclin A3 and antitumor activities in Ehrlich ascites carcinoma (EAC) cell based assay. The novel purine derivatives 13a,b demonstrated potent inhibitor activities with IC50 values of 14 ± 9 and 13 ± 9 μM, respectively. Additionally, compound 15a showed the highest potency (IC50 = 10 ± 6 μM) in EAC cell based assay. Molecular modeling study, including fitting to a 3D-pharmacophore model and their docking into cyclin dependant kinase2 (CDK2) active site showed high fit values and docking scores. 相似文献
13.
Taiji Goto Akiko Shiina Toshiharu Yoshino Kiyoshi Mizukami Kazuki Hirahara Osamu Suzuki Yoshitaka Sogawa Tomoko Takahashi Tsuyoshi Mikkaichi Naoki Nakao Mizuki Takahashi Masashi Hasegawa Shigeki Sasaki 《Bioorganic & medicinal chemistry》2013,21(22):7025-7037
5-Carbamoyl-2-phenylpyrimidine derivative 2 has been identified as a phosphodiesterase 4 (PDE4) inhibitor with moderate PDE4B inhibitory activity (IC50 = 200 nM). Modification of the carboxylic acid moiety of 2 gave N-neopentylacetamide derivative 10f, which had high in vitro PDE4B inhibitory activity (IC50 = 8.3 nM) and in vivo efficacy against lipopolysaccharide (LPS)-induced pulmonary neutrophilia in mice (ID50 = 16 mg/kg, ip). Furthermore, based on the X-ray crystallography of 10f bound to the human PDE4B catalytic domain, we designed 7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one derivative 39 which has a fused bicyclic lactam scaffold. Compound 39 exhibited excellent inhibitory activity against LPS-induced tumor necrosis factor alpha (TNF-α) production in mouse splenocytes (IC50 = 0.21 nM) and in vivo anti-inflammatory activity against LPS-induced pulmonary neutrophilia in mice (41% inhibition at a dose of 1.0 mg/kg, i.t.). 相似文献
14.
15.
Andreas Ritzén Rikke Sindet Morten Hentzer Nannette Svendsen Robbin M. Brodbeck Christoffer Bundgaard 《Bioorganic & medicinal chemistry letters》2009,19(12):3275-3278
This Letter describes the discovery of a novel series of mGluR5 positive allosteric modulators (PAMs). The lead compound, 11c, exhibits excellent potency (EC50 = 30 nM) in vitro, and reaches high brain levels in both rats and mice after oral administration. 相似文献
16.
Li Tang Wen-Hua Ma Yun-Long Ma Shu-Rong Ban Xiu-E Feng Qing-Shan Li 《Bioorganic & medicinal chemistry letters》2013,23(8):2380-2383
A series of novel 4-substituted benzoxazolone derivatives was synthesized, characterized and evaluated as human soluble epoxide hydrolase (sEH) inhibitors and anti-inflammatory agents. Some compounds showed moderate sEH inhibitory activities in vitro, and two novel compounds, 3g and 4j, exhibited the highest activities with IC50 values of 1.72 and 1.07 μM, respectively. Structure–activity relationships (SARs) revealed that introduction of a lipophilic amino acid resulted in an obvious increase in the sEH inhibitory activity, especially for derivatives containing a phenyl (3d, IC50 = 2.67 μM), pyrrolidine (3g, IC50 = 1.72 μM), or sulfhydryl group (3e, IC50 = 3.02 μM). Several compounds (3a–3g) were tested in vivo using a xylene-induced ear edema mouse model. Three compounds (3d, 3f, and 3g) showed strong anti-inflammatory activities in vivo which were higher than that of Chlorzoxazone, a reference drug widely used in the clinic. Our investigation provided a novel type of sEH inhibitor and anti-inflammatory agent that may lead to the discovery of a potential candidate for clinical use. 相似文献
17.
Craig A. Stump Ian M. Bell Rodney A. Bednar John F. Fay Steven N. Gallicchio James C. Hershey Richard Jelley Constantine Kreatsoulas Eric L. Moore Scott D. Mosser Amy G. Quigley Shane A. Roller Christopher A. Salvatore Steven S. Sharik Cory R. Theberge C. Blair Zartman Stefanie A. Kane Samuel L. Graham Harold G. Selnick Joseph P. Vacca Theresa M. Williams 《Bioorganic & medicinal chemistry letters》2010,20(8):2572-2576
A novel series of potent CGRP receptor antagonists containing a central quinoline ring constraint was identified. The combination of the quinoline constraint with a tricyclic benzimidazolinone left hand fragment produced an analog with picomolar potency (14, CGRP Ki = 23 pM). Further optimization of the tricycle produced a CGRP receptor antagonist that exhibited subnanomolar potency (19, CGRP Ki = 0.52 nM) and displayed a good pharmacokinetic profile in three preclinical species. 相似文献
18.
Iain R. Greig Emmanuel Coste Stuart H. Ralston Rob J. van’t Hof 《Bioorganic & medicinal chemistry letters》2010,20(18):5548-5551
Biphenylketones were identified as novel inhibitors of NFκB activation. Structure–activity studies led to the identification of compound 4c, which had good potency against osteoclasts (IC50 = 0.8 μM), showed oral activity, and was able to completely prevent inflammation and bone loss in vivo. 相似文献
19.
S.N. Suryawanshi Avinash Tiwari Santosh Kumar Rahul Shivahare Monika Mittal Padam Kant Suman Gupta 《Bioorganic & medicinal chemistry letters》2013,23(10):2925-2928
A novel series of triazole integrated phenyl heteroterpenoids have been synthesized and screened for their in vitro activity against intracellular amastigote form of Leishmania donovani. Among all tested compounds, compound 3a was found to be the most active with IC50 6.4 μM and better selectivity index (SI) 18 as compared to reference drugs, miltefosine and miconazole. When evaluated in vivo in L. donovani/hamster model, 3a has exhibited 79 ± 11% inhibition of parasite multiplication at 50 mg kg?1 × 5 days on day 7 post treatment. 相似文献
20.
Craig A. Stump Ian M. Bell Rodney A. Bednar Joseph G. Bruno John F. Fay Steven N. Gallicchio Victor K. Johnston Eric L. Moore Scott D. Mosser Amy G. Quigley Christopher A. Salvatore Cory R. Theberge C. Blair Zartman Xu-Fang Zhang Stefanie A. Kane Samuel L. Graham Joseph P. Vacca Theresa M. Williams 《Bioorganic & medicinal chemistry letters》2009,19(1):214-217
Rational modification of a previously identified spirohydantoin lead structure has identified a series of potent spiroazaoxindole CGRP receptor antagonists. The azaoxindole was found to be a general replacement for the hydantoin that consistently improved in vitro potency. The combination of the indanylspiroazaoxindole and optimized benzimidazolinones led to highly potent antagonists (e.g., 25, CGRP Ki = 40 pM). The closely related compound 27 demonstrated good oral bioavailability in dog and rhesus. 相似文献